<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756691</url>
  </required_header>
  <id_info>
    <org_study_id>PK-FAZ-003</org_study_id>
    <nct_id>NCT00756691</nct_id>
  </id_info>
  <brief_title>A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA</brief_title>
  <official_title>A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoxia (little of no oxygen) is considered to be an important characteristic of a patient's&#xD;
      tumour that may help predict patient outcomes and/or help inform patient management&#xD;
      decisions. 18F-FAZA Positron Emission Tomography (PET) can detect hypoxic tumours because&#xD;
      18F-FAZA accumulates in hypoxic tissues. This study is being done to learn more about the&#xD;
      processes by which 18F-FAZA is absorbed, distributed, metabolized (built-up and broken down)&#xD;
      and eliminated by the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I Radiopharmacokinetic and Radiodosimetric study of 18F-FAZA. Prior to treatment,&#xD;
      subjects will receive a single injection of 18F-FAZA. Subjects will undergo a series of 5-5&#xD;
      PET scans, and will have 8-13 blood samples and 2 urine samples taken at specified time&#xD;
      points over a 4.5-5.5 hour period. 18F-FAZA PET images will be reviewed to develop a dynamic&#xD;
      uptake model, and blood and urine samples will be analyzed for unchanged 18F-FAZA and its&#xD;
      metabolites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Limited scanner availability&#xD;
  </why_stopped>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To Collect imaging-based data for radiopharmacokinetic and radiodosimetric analyses.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine radiation dosimetry and optimal imaging times</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypoxic Tumours</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>First 5 consecutive 18F-FAZA avid subjects that undergo up to 5 PET scans, 13 blood and 2 urine samples over 4.5 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Next 5 consecutive 18F-FAZA avid subjects that undergo up to 4 PET scans, 8 blood and 2 urine samples over 5.5 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-FAZA</intervention_name>
    <description>Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known primary or suspected metastatic carcinoma of the following: squamous&#xD;
        cell carcinoma (SCC) of the head and neck, small (SCLC) and non-small cell lung&#xD;
        cancer(NSCLC), Glioblastoma multiforme (GBM), lymphoma, or neuroendocrine tumours (NET).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male of Female &gt; or = to 18 years of age. If female of child-bearing potential and&#xD;
             outside of the window of 10 days since the first day of the last menstrual period, a&#xD;
             negative pregnancy test required&#xD;
&#xD;
          -  Subjects with known primary or suspected metastatic SCC head and neck; NSCLC; SCLC;&#xD;
             GBM; lymphoma, or NET with at least one lesion &gt; 1 cm in diameter&#xD;
&#xD;
          -  Able and willing to follow instructions and comply with the protocol&#xD;
&#xD;
          -  Provide written informed consent prior to participation in the study&#xD;
&#xD;
          -  Karnofsky Performance Scale Score of 70-100&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment for their primary or metastatic SCC head and neck, NSCLC, SCLC,&#xD;
             GBM, Lymphoma, or NET&#xD;
&#xD;
          -  Bilirubin &gt; or = to 200 umol/L&#xD;
&#xD;
          -  Creatinine &gt; or - to 150 umol/L&#xD;
&#xD;
          -  AST or ALT &gt; or = to 5 times the upper limits of normal&#xD;
&#xD;
          -  Serious medical conditions such as: congestive heart failure, unstable angina,&#xD;
             unstable ventricular arrhythmia, uncontrolled psychiatric conditions, serious&#xD;
             infections, uncontrolled diabetes&#xD;
&#xD;
          -  Nursing or pregnant females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander McEwan, MB, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Department of Oncology</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>18F-FAZA</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Radiation dosimetry</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoroazomycin arabinoside</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

